Reflecting on a milestone year: Prescient Therapeutics readies for next stage in cancer battle
Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as...
Australian biotech company Prescient Therapeutics has achieved numerous milestones in the past financial year as...
Australia-based clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX) has completed another action-packed year with a...
Steven Yatomi-Clarke from Prescient Therapeutics (ASX:PTX)
Prescient Therapeutics has announced that a global expert in brain cancer, Professor Donald M. O’Rourke,...
Steven Yatomi-Clarke – CEO & Managing Director – Prescient Therapeutics is focused on developing novel, personalised therapies for...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
The appointment gives PTX a world-leading development team in the race to find solutions for...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
Researchers at the University of Pennsylvania (Penn) are developing a new way for cancer-fighting CAR-T...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins Small Caps...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.